Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hamid Emamekhoo

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
Journal for Immunotherapy of Cancer|March 12, 2022
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)Douglas G McNeel, Jens C Eickhoff, Ellen Wargowski, et al.
Cancers|May 13, 2023
Understanding the Tumor Immune Microenvironment in Renal Cell CarcinomaDaniel D Shapiro, Brendan Dolan, Israa A Laklouk, et al.
Cancer|May 24, 2023
Getting ready for real-world use of electronic patient-reported outcomes (ePROs) for patients with cancer: A National Comprehensive Cancer Network ePRO Workgroup paperJennifer R Cracchiolo, Waddah Arafat, Ashish Atreja, et al.
Investigational New Drugs|September 4, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genesKaren A Autio, Christos E Kyriakopoulos, Paul Palyca, et al.
Abdominal Radiology (New York)|February 22, 2018
Percutaneous microwave ablation for local control of metastatic renal cell carcinomaKimberly A Maciolek, E Jason Abel, Sara L Best, et al.
Frontiers in Oncology|November 16, 2020
Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional CohortPedro Barata, Whitley Hatton, Arpita Desai, et al.
The Oncologist|April 11, 2020
Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial CancerMing Yin, Petros Grivas, Qi-En Wang, et al.
Oncotarget|May 24, 2016
Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinomaMonika Joshi, Monali Vasekar, Petros Grivas, et al.
Cancer|February 17, 2026
Deriving wisdom from data: The value and continued rationale for structured data in the era of artificial intelligence-driven oncology careHamid Emamekhoo, Irbaz B Riaz, Daniel B Martin, et al.
Clinical Genitourinary Cancer|March 20, 2018
Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial CarcinomaHamid Emamekhoo, Puneet Dhillon, Dharmesh Gopalakrishnan, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|March 12, 2022
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)Douglas G McNeel, Jens C Eickhoff, Ellen Wargowski, et al.
Cancers|May 13, 2023
Understanding the Tumor Immune Microenvironment in Renal Cell CarcinomaDaniel D Shapiro, Brendan Dolan, Israa A Laklouk, et al.
Cancer|May 24, 2023
Getting ready for real-world use of electronic patient-reported outcomes (ePROs) for patients with cancer: A National Comprehensive Cancer Network ePRO Workgroup paperJennifer R Cracchiolo, Waddah Arafat, Ashish Atreja, et al.
Investigational New Drugs|September 4, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genesKaren A Autio, Christos E Kyriakopoulos, Paul Palyca, et al.
Abdominal Radiology (New York)|February 22, 2018
Percutaneous microwave ablation for local control of metastatic renal cell carcinomaKimberly A Maciolek, E Jason Abel, Sara L Best, et al.
Frontiers in Oncology|November 16, 2020
Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional CohortPedro Barata, Whitley Hatton, Arpita Desai, et al.
The Oncologist|April 11, 2020
Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial CancerMing Yin, Petros Grivas, Qi-En Wang, et al.
Oncotarget|May 24, 2016
Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinomaMonika Joshi, Monali Vasekar, Petros Grivas, et al.
Cancer|February 17, 2026
Deriving wisdom from data: The value and continued rationale for structured data in the era of artificial intelligence-driven oncology careHamid Emamekhoo, Irbaz B Riaz, Daniel B Martin, et al.
Clinical Genitourinary Cancer|March 20, 2018
Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial CarcinomaHamid Emamekhoo, Puneet Dhillon, Dharmesh Gopalakrishnan, et al.
Pageof 7